In another approach, intratumoral injection of DCs transduced with SFV particles expressing interleukin-18 (IL-18) in combination with recombinant IL-12 protein therapy, elicited Th1-type immune responses and provided anti-tumor immunity in a B16 brain tumor mouse model [120]. The gene discussed is IL18; the disease is brain neoplasm.